Embla Medical Hf S/Adr (OSSUY) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Embla Medical Hf.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.955 Welcome to EMPLA Medical Conference Call for Q2 2025. 00:00:04.998 -- 00:00:09.584 Today's call is being recorded. If you have any objections, please disconnect at this 00:00:09.584 -- 00:00:14.712 time. All participants will be in a listen-only mode throughout the presentation. 00:00:14.712 -- 00:00:17.816 Afterwards, there will be a question and answer session. 00:00:17.816 -- 00:00:22.262 To ask a question, please press 5 star on your telephone keypad. 00:00:22.262 -- 00:00:27.470 I would now like to introduce President and CEO Svend Sulvason and CFO Arne 00:00:27.470 -- 00:00:31.272 Svensdottir. Please begin your presentation. 00:00:32.228 -- 00:00:37.276 Thank you very much, and good morning, and welcome to the Ampla Medical Conference Call, 00:00:37.276 -- 00:00:40.901 where we will review the second quarter of 2025. 00:00:40.901 -- 00:00:44.246 I'm Fred Sjölandson, President and CEO of Ampla Medical. 00:00:44.246 -- 00:00:48.593 Joining me on today's call is our Chief Financial Officer, Arne Svensdorf, and Ampla 00:00:48.593 -- 00:00:52.857 Medical's Head of the Investor Relations, Klaus Sinter. 00:00:52.920 -- 00:00:57.266 The presentation should take approximately 15 minutes, after which there will be an opportunity 00:00:57.266 -- 00:01:03.892 to ask questions during a Q&A session. If we go to the next slide, please. 00:01:04.516 -- 00:01:07.840 Sales in the second quarter amounted to 232 00:01:07.840 -- 00:01:11.425 million, representing 7% reported 00:01:11.425 -- 00:01:14.450 growth, of which 5% was organic. 00:01:14.450 -- 00:01:18.535 Growth was strong in the prosthetics and neuro-orthotics segment, mainly driven by the 00:01:18.535 -- 00:01:23.883 continued momentum in MEA, and supported by solid contributions from ...